Prof. Dr. Carol Moreno received her PhD in Medicine in 2006, working at the Hospital Clínic of Barcelona, where she studied the status of minimal residual disease in patients with CLL submitted to stem cell transplantation and its prognostic impact on outcome. She amplified her knowledge in CLL cellular biology in the Feinstein Institute for Medical Research, New York, during a 2-year postdoctoral stage and now she is working in Barcelona as a Consultant at the Department of Hematology in the Hospital Santa Creu i Sant Pau where she combines her clinical work as hematologist in the Department of Hematology with her research activity in the CLL Research group located in the Biomedical Research Institute of Sant Pau (IIB-Sant Pau).
Her research interest has been the characterization of residual leukemic cells, autoimmunity and mechanisms involved in BCR signaling. On these topics she published over 70 manuscripts in peer-reviewed journals. She also participates and is a Board Member of "European Research Initiative for Chronic Lymphocytic Leukemia" (ERIC) where she has been involved in the definition of guidelines for the analysis of the mutational status of the Immunoglobulin genes in CLL and standardization of flow cytometry techniques for the assessment of minimal residual disease (MRD).